These include FAK inhibitors [80], Hedgehog inhibitors [81], fibroblast growth factor receptor (FGFR) inhibitors [82], connective tissue growth factor (CTFG) antagonists [83], and TGF-β inhibitors [84], all of which target tumor cells’ ability to activate neighboring fibroblasts. The gene discussed is CCN2; the disease is neoplasm.